A Spanish research centre, has jointly developed with a Israeli university, a family of compounds able to inhibit Semaphorin3A fostering nerve regeneration after injury. These compounds can be useful for treatment of ischemic events such as stroke, glaucoma and other optical nerve and retina insults. Biotech or pharmaceutical companies are sought for license agreement and/or research collaboration to perform preclinical assays. After a neuronal damage is...
Read MoreThis website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.